🇺🇸 FDA
Patent

US 10556945

Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 10556945 (Antagonist antibodies directed against calcitonin gene-related peptide and methods using same) held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICALS INTERNATIONAL GMBH
Grant date
Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/55